Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy

@article{Androdias2011MycophenolateMM,
  title={Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy},
  author={G{\'e}raldine Androdias and Didier Maillet and Romain Marignier and Laurent Pin{\`e}de and Cyrille B. Confavreux and Christiane Broussolle and Sandra Vukusic and Pascal S{\`e}ve},
  journal={Neurology},
  year={2011},
  volume={76},
  pages={1168 - 1172}
}
Objective: To describe effectiveness, steroid-sparing effect, and tolerance of the antiproliferative immunosuppressant mycophenolate mofetil (MMF) in neurosarcoidosis. Methods: We describe a retrospective case series of 10 consecutive patients with a diagnosis of neurosarcoidosis who were treated with MMF, alone or in association with corticosteroids, in our teaching hospital. Results: At the time of our study, the mean duration of MMF treatment was 21 months. All but one patient with CNS… Expand
Effect and Safety of Mycophenolate Mofetil in Chronic Pulmonary Sarcoidosis: A Retrospective Study
TLDR
This study indicates that the addition of MMF to corticosteroids is a viable and safe treatment option in CPS, and allows a significant reduction of maintenance cortICosteroids to levels <10 mg/day while preserving a stable or improved clinical condition. Expand
Management of Cardiac Sarcoidosis Using Mycophenolate Mofetil as a Steroid Sparing Agent.
TLDR
MMF in combination with prednisone for treatment of CS may minimize corticosteroid exposure and reduce cardiac inflammation without significant adverse effects. Expand
Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients
TLDR
The results suggest that MMF can improve or stabilise MS patients and can be used as an alternative therapy. Expand
Treatment of neurosarcoidosis
TLDR
This study provides Class IV evidence that for patients with neurosarcoidosis taking steroids, MTX is superior to MMF in reducing the risk of relapse and should be preferred over MMF for the treatment of neurosaruidosis. Expand
Cytotoxic agents in sarcoidosis: which one should we choose?
TLDR
A better insight into the advantages and disadvantages of second-line and third-line treatment is important and the long-term effects of immunosuppressive agents, the optimal starting and maintenance dosages, and the best interval and discontinuation regimens should be elucidated. Expand
Refractory Sarcoidosis: A Review
TLDR
Refractory sarcoidosis is considered as a disease in which second-line treatments are not sufficient to achieve satisfying disease control or satisfying corticosteroids tapering, and Methotrexate is the only first-line immunosuppressant validated by a randomized controlled trial. Expand
Knowing when to use steroids, immunosuppressants or biologics for the treatment of sarcoidosis
TLDR
Care of patients with sarcoidosis requires familiarity with its natural history as well as of various immunosuppressants employed in its treatment, and adopting a strategy of early SSAS therapy ought to effectively control sarcoIDosis and avoid harm from prolonged corticosteroid dosing. Expand
Sarcoidosis: an update on current pharmacotherapy options and future directions
TLDR
This review summarizes current pharmacotherapy options and future directions for the development of new therapies for sarcoidosis, with monoclonal anti-TNF agents being the most promising. Expand
Treatment of Neuro-Ophthalmic Sarcoidosis
  • L. Frohman
  • Medicine
  • Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • 2015
TLDR
Although methotrexate and mycophenolate mofetil are the medications that are often selected after corticosteroid failure, more rapidly acting agents that have been used are infliximab and intravenous cyclophosphamide. Expand
Management of extrapulmonary sarcoidosis: challenges and solutions
TLDR
Clinicians need to assess patients comprehensively using clinical, laboratory, imaging, and histopathological data to recommend competently the best and least toxic treatment option for the individual patient. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 13 REFERENCES
Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil
TLDR
Combination treatment with mycophenolate mofetil and infliximab is a promising therapeutic approach for neurosarcoidosis. Expand
Mycophenolate Mofetil Therapy for Sarcoidosis-Associated Uveitis
TLDR
It is suggested that MMF is effective in controlling sarcoidosis-related ocular inflammation, has a corticosteroid sparing effect and a manageable side-effect profile. Expand
[Neurosarcoidosis treated with mycophenolate mofetil: two cases].
TLDR
The MMF seems to be an interesting rescue treatment for neurosarcoidosis, with significant and rapid effectiveness was clinically and radiologically observed, with good clinical and hematologic tolerance. Expand
Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients.
TLDR
Almost half of all patients with NS seen at the Allegheny Neurological Clinic were believed to have disabling disease and to be at high risk for disease progression, and these high-risk patients were treated with corticosteroids plus alternative immunosuppressive therapy, and favorable outcomes were obtained in almost all patients. Expand
Granulomatous myositis: A clinical study of thirteen cases
TLDR
Granulomatous myositis was frequently associated with severe disability and rarely improved after corticosteroid treatment, whereas most patients with isolated GM improved. Expand
Neurosarcoidosis: a clinical dilemma
TLDR
The clinical manifestations of neurosarcoidosis, diagnostic dilemmas and considerations, and therapy are described, and the value of new drugs such as anti-tumour necrosis factor alpha will be assessed. Expand
Mycophenolate Mofetil
TLDR
The benefits in terms of a reduction in the morbidity associated with acute organ allograft rejection indicate that mycophenolate mofetil should be considered as part of a primary therapy regimen in renal and cardiac transplant recipients, and as a treatment for reversal of acute refractory rejection in these patients. Expand
Presentations and outcomes of neurosarcoidosis: a study of 54 cases.
TLDR
There is difficulty in making tissue diagnosis when involvement of CNS is suspected and MRI and CSF studies are sensitive in the detection of CNS inflammation but lack specificity, making the ascertainment of neurosarcoidosis a clinical challenge. Expand
Sarcoidosis: Clinical, Hormonal, and Magnetic Resonance Imaging (MRI) Manifestations of Hypothalamic-Pituitary Disease in 9 Patients and Review of the Literature
TLDR
Hormonal deficiencies associated with HP sarcoidosis frequently include hypogonadism (all patients) and to a lesser degree diabetes insipidus (7 of 9 patients). Expand
Spinal cord sarcoidosis: report of seven cases
TLDR
This study highlights the need to understand more fully the mechanism behind spinal cord involvement in sarcoidosis before deciding whether or not to operate on patients with spinal cord injuries. Expand
...
1
2
...